AdvanCell is a radiopharmaceutical company developing next-generation cancer treatments

AdvanCell’s targeted alpha therapies are powered by a platform technology – a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy – the reliable and scalable supply of isotope.


Our Vision

Radioligand therapy is disrupting cancer treatment providing new hope for patients with untreatable cancers.

The approach can improve survival and quality of life by precisely targeting the cancer with radiation.

The major limitation to widespread adoption is the scalable supply of the isotopes required to make these therapies a reality for every patient. AdvanCell is committed to overcome this limitation and 'Change the Course of Cancer Treatment'.


Team

The AdvanCell team has deep experience across nuclear materials science, radiopharmaceutical development and production, clinical application and business development. The team is delivering an end-to-end solution from isotope production and drug development to treatment.

Andrew Adamovich

BA

Managing Director

Andrew is a founder and Managing Director of AdvanCell Isotopes. Prior to AdvanCell Isotopes, Andrew led investment activities for Riverland Capital, a private investment firm, where as a founder and director he focused on investing in China. Andrew is a director of G2 Therapies, a spinout from the Garvan Institute, and is a director of CGI Glass Lewis, the Australian affiliate of Glass Lewis, a corporate governance advisory firm. Andrew was a director and shareholder of Yuan Chuan Radio (sold to Shanghai-listed Orient Securities), ASX-listed Hostworks Group (sold to Broadcast Australia), amongst other listed and private companies. Andrew began his career at Peregrine Investments in Hong Kong in 1997 and holds a Bachelor of Arts degree from University of California, Berkeley. Andrew is an experienced investor in healthcare and is responsible for business development for AdvanCell and corporate activities for the Company.

Read more

Dr Mike Fay

MBCHB FRACP FRANZCR PHD

Director & Chief Medical Officer

Mike is a medical doctor with dual training in Radiation and Medical Oncology. Mike did his undergraduate degree in New Zealand, and has worked clinically in New Zealand, Australia, the UK and the US and spent research time in Germany (Universität Tübingen).  Mike has a PhD in the development and clinical translation of theranostics, and has led a number of clinical trials both in cancer and theranostics. Mike has sat on the faculty board of the Royal Australasian College of Radiologists and of CannaPacific (a biotech startup). Mike is a Senior Lecturer at the Universities of Queensland and Newcastle and has published 79 papers and book chapters.  Mike has received more than $4.5 million in competitive grant funding, and has worked with colleagues at CSIRO on a number of theranostics research projects over the past decade.

Read more

Dr Julian F. Kelly

B.Sc (Hons) PHD

Chief Nuclear Scientist

Julian has over 20 years of expertise working with & managing nuclear & radioactive materials. He has a PhD in chemical physics (ANU), and over 10 years of experience developing IP on the innovative uses of radiation and radioactive materials. Julian held scientific roles at CSIRO, the Defence Intelligence Organisation, and at the Australian Nuclear Science and Technology Organisation (ANSTO). Julian served as Nuclear Attaché in the Australian Embassy in Vienna, representing Australia on technical nuclear matters at the UN’s International Atomic Energy Agency.

Read more

Dr Simon Puttick

PHD

Chief Technology Officer

Simon completed a PhD in Chemistry at the University of Nottingham in 2012 where his study was focused on the use of nuclear magnetic resonance spectroscopy to understand the spatial organisation of ionic liquids. Following his PhD, Simon moved to the University of Cambridge as a Research Fellow focused on the discovery of magnetic resonance imaging biomarkers of neurodegeneration in Huntington's Disease. Simon moved to Australia in 2013 to take up a position as a Research Fellow at the University of Queensland focused on the development of targeted radionuclide therapies for primary brain cancers. In this position Simon developed a keen interest in the field of nuclear medicine and has developed a portfolio of active research in this field. Simon moved to CSIRO in 2018 to lead a program of research in targeted alpha therapy development and remains a visiting scientist. Simon joined AdvanCell as Chief Technology Officer in 2021 to realise the potential of the AdvanCell's targeted alpha therapy portfolio.

Read more

Professor Stephen Rose

PHD

Head of Clinical Development

Professor Rose has over 25 years’ experience in clinical R&D within the academic sector along with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national science agency. He works closely with clinicians developing the next generation of molecular imaging, therapeutic and diagnostic platforms targeting oncology sector. Before joining AdvanCell, Prof Rose was director of a prestigious CSIRO Future Science Platform, a highly successful $35m research program with over 30 FTE scientific staff at the PhD level to drive innovation in the Medical Technologies and Pharmaceuticals sector. This included targeting the development of novel theranostic platforms for improved delivery of novel alpha radioligand therapies for difficult to treat cancers. During this career, Prof Rose has made a significant contribution to obtaining competitive funding from various national medical research funding bodies (NHMRC, MRFF), state government R&D initiatives, the international pharmaceutical industry and private medical service providers. In terms of impact on health, he introduced to Australia a new PET tracer (F18-FEOBV) to measure cholinergic function in dementia patients and was instrumental in establishing clinical molecular imaging research program using MRI, F18-FDOPA and F18-FMISO PET to improve care pathways for patients with brain cancer. Prof Rose has played a major role of bringing new liquid biopsy diagnostic tests to the clinic. One example being the development of NeuroLiB; the first epigenetic ccfDNA assay for detecting neural injury currently being validated through a prospective clinical trial. He was also instrumental in establishing a $5 million theranostics discovery R&D program with GenesisCare, the largest private providers of cancer care services in Australia. Prof Rose has published more than 240 manuscripts in international peer reviewed journals. In terms of general citation indices, his work has been cited 11900 times and his h-index is 52.

Read more

Kevin K. W. Kuan

PHD

Head of Product Development and Director of Operations

Dr Kuan received his PhD in the field of synthetic organic chemistry from the University of Adelaide in 2016 studying biometric synthesis of marine natural products. He joined AdvanCell in October 2021 and is currently Head of Product Development and Director of Operations. Prior to joining the company, Dr. Kuan was the Head of Chemistry and Product Development at Clarity Pharmaceuticals, where he led the company’s radiopharmaceutical product development and manufacturing operations across all stages of clinical development. Dr. Kuan held various roles of increasing responsibility at the Molecular Imaging and Therapy Research Unit (MITRU), a TGA licensed cyclotron facility belonging to the South Australian Health and Medical Research Institute (SAHMRI). During his tenure at SAHMRI, Dr. Kuan was responsible for the implementation and supply of Investigational Medicinal Products for clinical trials and the development of radiometals on cyclotron solid targetry systems. Key highlights included overseeing the validation and supply of [64Cu]copper chloride API, [177Lu]Lu-PSMA-617, [177Lu]Lu-PSMA-I&T, [18F]PSMA-1007, [64Cu]Cu-SARTATE, [64Cu]Cu-ATSM and [18F]GE-180.  He holds a patent for Formulations of PSMA Imaging Agents (Australian Patent No. AU 2019901765) and is a Member of the Royal Australian Chemistry Institute (MRACI) and the Australian and New Zealand Society of Nuclear Medicine (ANZSNM)

Read more

William Tieu

PHD

Head of Chemistry

Dr Tieu holds a PhD in Chemistry from the University of Adelaide and completed a post-doctoral fellowship at the University of Sydney where he developed novel radiopharmaceuticals. He joined AdvanCell Isotopes in October 2021 and is Head of Chemistry. Dr Tieu has over 11 years’ experience in drug development, project management and GMP manufacturing. Prior to joining AdvanCell Isotopes, Dr Tieu was the Senior Research Radiochemist at South Australian Health and Medical Research Institute, with responsibility for managing the development of over a dozen radiopharmaceutical and radioisotope products. His role also included scientific contribution to numerous chemistry, radiation and pre-clinical studies. During this period, he was part of a team who helped develop several radiopharmaceuticals including [18F]FDOPA, MK6240, [64Cu]Cu-peptides, [64Cu]Cu-ATSM, [89Zr]Zr-mAbs and production of various imaging isotopes including 68Ga, 89Zr, 45Ti and ²⁰³Pb. Dr Tieu also has experience with manufacturing of 89Zr-mAbs for a first in human Phase 1 clinical trials. He has 26 publications and 2 patents with his work has been cited more than 443 times. His h-index is 13.   Dr Tieu is a current member of the Australian and New Zealand Society of Nuclear Medicine. 

Read more

Vanessa Worsfold

BBioTech

Head of Quality

Vanessa has 15 years’ experience in medical diagnostics and devices specialising in the establishment and maintenance of quality management systems, global regulatory market access and commercialisation of products. Vanessa has also held leadership roles in manufacturing and marketing, and is currently completing an MBA. Vanessa holds a Bachelor of Biotechnology and a Graduate Certificate in Management.

Read more

Sheridan Martin

BTechFACH BSc (Hons)

Regulatory Affairs Manager - Nuclear

Sheridan has more than eight years’ experience in radiation safety and regulatory affairs management including serving as CSIRO’s Chief Radiation Safety Officer for almost four years before joining AdvanCell in March 2022. Sheridan completed her Honours degree in Chemistry at Flinders University in 2009 with a focus on the development of analytical methods for anticonvulsant pharmaceuticals with Forensic Science South Australia. She started with CSIRO in 2010 as an analytical research technician in CSIRO Land and Water’s environmental contaminants team before transitioning to CSIRO’s Health, Safety and Environment team in 2016. Sheridan was instrumental in driving key regulatory and radiation safety initiatives within CSIRO, including leading a multi-million-dollar project to consolidate and characterise CSIRO’s legacy waste holdings.

Read more

Nicolo Canever

MSC PHD

Senior Research Scientist

Dr Canever earned a master’s degree in chemistry from the University of Padova (Italy), and a PhD in chemistry from Victoria University of Wellington, New Zealand, with a thesis titled “Electrode nanomaterials and electrolytes for Aluminium-ion batteries”. As an early-career researcher, he authored several academic publications originating from his work. He joined the AdvanCell team in early 2021 and has recently taken on a full-time position as a research scientist. Before joining AdvanCell, he worked as a Postdoctoral Research Associate at the University of Newcastle, where he conducted research in the field of energy storage and nanomaterials, both through individual work and the supervision of small research project by undergraduate students. As part of this position, he contributed to the supervision of an internship sponsored by AdvanCell.

Read more

Peter Whitfeld

PHD

Company Secretary

Dr Peter Whitfeld has over 30 years’ experience in biotechnology research & development and in intellectual property and contracts management. Peter is company secretary and general manager at G2 Therapies, a privately funded biotechnology company established to develop and commercialise novel antibody-based therapies. Most recently, he was a Senior Contracts Manager in the Legal Office at the Garvan Institute of Medical Research, having also been a senior manager in the Partnerships and Business Development Office at Garvan. Prior to those roles Peter managed the C5aR program at G2, lead the team responsible for humanising G2's therapeutic antibodies and worked with Novo Nordisk to further develop the anti-C5aR mAb for clinical trials. Before joining G2 and the Garvan, Dr Whitfeld held senior research and managerial positions at GroPep and Biotech Australia. He held post-doctoral research positions at CSIRO, Fox Chase Cancer Center and Prince Henrys Institute for Medical Research. Peter completed a PhD at the Australian National University, Research School of Biological Sciences and a Masters in Drug Development at UNSW.

Read more

Board of Directors

AdvanCell is privileged to have an experienced Board of Directors, with members who are leaders from venture capital, nuclear science and corporate governance.

Bill Ferris

AC

Chair

Bill is the Chair of the Board of Directors for the Company.  Bill was appointed Chair of the Medical Research Commercialisation Fund (MRCF) in March 2020, the largest source of funding in Australia for the development and commercialisation of early stage bio-medical discoveries providing both the capital and expertise to guide the successful emergence of new therapies.  Bill was the inaugural Chair of Innovation and Science Australia from 2015 to 2018. Bill's former recent directorships include: Chairman, Garvan Institute of Medical Research and Chair of the Federal Government’s Health and Hospitals Fund Advisory Board. Other former directorships include: Chairman, Accolade Wines Australia and UK, Austar United Communications, Australian Trade Commission (Austrade); Macquarie University Asia Pacific Council; and Director, Garvan Research Foundation, Austal Ltd and Australian Institute of Management (NSW) Ltd. Bill also joined the expert panel for the Federal Government’s Strategic Review of Health and Medical Research in October 2011 and was a member of the Harvard Business School Asia Pacific Advisory Council from 2010 – 2019. Bill was awarded an Officer of the Order of Australia in 1990 for services to the export industry and in 2008 was made Companion in the Order of Australia for his philanthropic activities, as a leader in support of medical research and his role in the establishment of the private equity sector in Australia. Bill is the author of 3 books: “Really Making a Difference” published December 1993, “Nothing Ventured, Nothing Gained” published March 2000, and “Inside Private Equity”, published January 2013. 

Read more

Kevin Cameron

Director

Kevin is CEO at Ionetix Corporation. Prior to joining Ionetix in 2011, Mr. Cameron served as President of Glass, Lewis & Co., a leading independent corporate governance research firm which he co-founded in 2003.  Prior to Glass Lewis, he served as General Counsel at Moxi Digital, a technology venture founded by Microsoft co-founder Paul Allen. Mr. Cameron previously served as General Counsel at NorthPoint Communications, a publicly-traded broadband telecommunications company acquired by AT&T.  Before NorthPoint, he was an attorney with the corporate law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C. and served as a law clerk to the Hon. James L. Buckley of the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron is a director of KERYX Biopharmaceuticals (NASD:KERX), a director of AvidBiotics, a former director of Reddy Ice, and was a founding board member of ProCure Treatment Centers, the leading provider of proton therapy treatment in the U.S. He earned a J.D. from the University of Chicago and a B.A. at McGill University.

Read more

Dr Adrian (Adi) Paterson

BSC, PHD

Director

Dr Adi Paterson has a strong public science and senior management background, operational and strategic management expertise and the  in the commercialisation of scientific research - including nuclear programs and applications. Dr Paterson led the Australian Nuclear Science and Technology Organisation (ANSTO) from 2009 until September 2020.  Prior to joining ANSTO, he was General Manager, Business Development and Operations at the Pebble Bed Modular Reactor Company in South Africa. From March 2009 to September 2020 Adi had strategic oversight and responsibility for ANSTO’s multi-facetted portfolio of activities. Dr Paterson has a track record of generating positive change and growth. Putting people first, with a focus on diversity and inclusion, underpins the transformation process. This has leveraged outcomes based on the nexus of public science investment and practical innovation with positive impacts on health, industry and the environment. ANSTO operates the multi-purpose Open Pool Australian Light-water (OPAL) Reactor which provides access to neutrons for science and irradiation services for Australian and overseas users. Dr Paterson oversaw the integration of the Australian Synchrotron into ANSTO operations in 2016 and secured funding for a major capital program for eight new beamlines. This broadens opportunities for the extensive user communities in Australia, New Zealand and overseas. Dr Paterson’s focus on the importance of diversity, inclusion and equity, particularly in STEM, led to his appointment in 2016 as a Male Champion of Change for STEM. Dr Paterson has experience in key policy areas including science and innovation, energy and the nuclear fuel cycle.  He is a Fellow of the Australian Academy of Technology and Engineering (ATSE), Engineers Australia (EA), and the Royal Society of New South Wales. The Sydney Division of Engineers Australia recognised him as the 2012 Professional Engineer of the Year. Dr Paterson holds a BSc (Chemistry) and a PhD (Engineering), both from the University of Cape Town. He was awarded an Honorary Doctorate by the University of Wollongong in 2017.

Read more

Andrew Adamovich

BA

Managing Director

Andrew is a founder and Managing Director of AdvanCell Isotopes. Prior to AdvanCell Isotopes, Andrew led investment activities for Riverland Capital, a private investment firm, where as a founder and director he focused on investing in China. Andrew is a director of G2 Therapies, a spinout from the Garvan Institute, and is a director of CGI Glass Lewis, the Australian affiliate of Glass Lewis, a corporate governance advisory firm. Andrew was a director and shareholder of Yuan Chuan Radio (sold to Shanghai-listed Orient Securities), ASX-listed Hostworks Group (sold to Broadcast Australia), amongst other listed and private companies. Andrew began his career at Peregrine Investments in Hong Kong in 1997 and holds a Bachelor of Arts degree from University of California, Berkeley. Andrew is an experienced investor in healthcare and is responsible for business development for AdvanCell and corporate activities for the Company.

Read more

Dr Mike Fay

MBCHB FRACP FRANZCR PHD

Director & Chief Medical Officer

Mike is a medical doctor with dual training in Radiation and Medical Oncology. Mike did his undergraduate degree in New Zealand, and has worked clinically in New Zealand, Australia, the UK and the US and spent research time in Germany (Universität Tübingen).  Mike has a PhD in the development and clinical translation of theranostics, and has led a number of clinical trials both in cancer and theranostics. Mike has sat on the faculty board of the Royal Australasian College of Radiologists and of CannaPacific (a biotech startup). Mike is a Senior Lecturer at the Universities of Queensland and Newcastle and has published 79 papers and book chapters.  Mike has received more than $4.5 million in competitive grant funding, and has worked with colleagues at CSIRO on a number of theranostics research projects over the past decade.

Read more

Scientific Advisory Board

AdvanCell is honoured to be advised by some of the leading experts in the fields of nuclear medicine, radiochemistry and pharmacology.

Prof. Dr Ken Herrmann

MBA

Prof. Dr. Ken Herrmann, MBA graduated from Charite Berlin Medical School in 2004 after completing away electives and ERASMUS exchanges in France, Switzerland, Chile and the US. In 2007 he received the Doctors Degree from Humboldt Universität Berlin with his work "Expression and function of A1 adenosine receptors in gliomas“. In 2011 he completed the executive MBA program at Universität Zürich, Switzerland. Professor Herrmann completed his residency in Nuclear Medicine at Klinikum rechts der Isar, Technische Universität München, as well as his habilitation titled "In Vivo-Proliferation Imaging with 3´deoxy-3´-[18F]Fluorothymidine PET in Oncology“. In May 2011 he joined as Visiting Assistant Professor and was later promoted to tenure track Associate Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). From August 2012 to July 2016 he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg. Since August 2016 Professor Herrmann acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen and as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA. He also is currently the Chair of the EANM Oncology & Theranostics committee and Section Editor of the Journal of Nuclear Medicine.

Read more

Clemens Kratochwil

MD

Dr. Kratochwil studied medicine at the University of Ulm in Germany. After graduating from medical school, his residency led him through the Departments of Nuclear Medicine of the University Hospital Ulm, Technical University Munich and Heidelberg University Hospital. He received his Doctors Degree (“18F-FLT for monitoring treatment response”) in 2008. Since 2010 he worked as a consultant and since 2013 as the supervising physician of the radionuclide ward of Heidelberg University Hospital. His clinical and preclinical scientific interest is focused on targeted alpha-emitter therapy. Work related to 213Bi-Dotatoc was decorated with the SNM Nuclear Oncology Council Young Investigator Award and the RSNA Trainee Research Prize in 2011. Work related to 225Ac-PSMA617 with the EANM Marie Curie Award and the Therapy Award of the German society of Nuclear Medicine. Using ²⁰³Pb surrogate imaging, he explored PSMA-ligands with favorable characteristics for ²¹²Pb labeling. As a nuclear medicine professional and researcher, he already (co)authored approx. 180 peer-reviewed articles.

Read more

Martin W. Brechbiel

Ph.D.

Dr. Brechbiel is Scientist Emeritus at the the National Cancer Institute, Radioation Oncology Branch. Dr. Brechbiel is a leading authority on the development of the chemistry required for effective targeted radiation therapy and imaging chemistry. His studies have led to initiation of multiple clinical trials, including those employing α-emitters 213Bi and ²¹²Pb. Basic coordination chemistry studies have also addressed the synthesis and in vivo validation of novel agents that have been translated through from pre-clinical studies to clinical use onwards to commercial products for both imaging and therapy of cancer.

Read more

Prof. Jenny Martin

MBChB, FRACP, MA (Oxon.), PhD, GAICD, AAHMS

Chair of Clinical Pharmacology in the School of Medicine and Public Health at the University of Newcastle. Leads team of pharmacy and medicine experts in Hunter New England Local Health District together with pharmacoepidemiologists and pharmacoeconomists, across several areas including cancer. Most often focusing on therapeutic drugs, the team look at everything from the design and development of drugs, to the clinical trials process, through to the post-marketing phase, where data is collected on how effective those drugs are in practice, and any side effects they might have.

Read more

David MacFarlane

Developed enduring interest in radiopharmaceutical therapy and oncologic nuclear medicine during Fellowship at the University of Michigan, Ann Arbor. Joined GenesisCare to pursue interest in Theranostics after serving as Deputy Director of Nuclear Medicine at Royal Brisbane Hospital, and senior staff specialist at Austin Health and Gold Coast University Hospital. Author on 40 peer-reviewed publications, participated in Phase I-III clinical trials of diagnostic and therapeutic agents and serves as medical monitor.  Adjunct Associate Professor with the University of Queensland School of Clinical Medicine.

Read more

Dominique Scott

Dominique (Dom) is a Senior Radiochemist employed by Royal Brisbane and Women’s Hospital (RBWH) and completing a Masters of Philosophy in the field of Radiochemistry through the University of Queensland. Dom has almost a decade of experience within the Radiopharmaceutical industry, in both the private and public sectors. During this time, Dom developed and implemented the first clinical use of sodium [124I]iodide (dosimetry of thyroid cancers) and [68Ga]gallium exendin-4 (localisation and detection of insulinomas) in Queensland. Over her career, Dom has assisted two facilities in gaining a TGA licensing and is knowledgeable in aseptic production of pharmaceuticals under a clean room environment. As a radiochemist, Dom has extensive experience with production and quality control testing of various diagnostic and therapeutic positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals.

Read more